System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Multicenter Study Ppublish 7 citations

PubMed: 31902591 DOI: 10.1016/j.ejso.2019.12.005

Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients.

Eur J Surg Oncol 46(5):862-867

Authors: Jean-Baptiste Delhorme, Jordan Ohayon, Sébastien Gouy, Gerlinde Averous, Catherine Genestie, Léopold Gaichies, Olivier Glehen, Jean-Marc Guilloit, Denis Pezet, Francois Quenet, Gwenaël Ferron, Cécile Brigand, Philippe Morice, Charles Honoré

Affiliations

  • Department of Surgical Oncology, Gustave Roussy Cancer Campus, 114, rue Edouard vaillant, 94800, Villejuif, France; Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University Hospital, 1 avenue Molière, 67200, Strasbourg, France.
  • Department of Surgical Oncology, Gustave Roussy Cancer Campus, 114, rue Edouard vaillant, 94800, Villejuif, France.
  • Department of Gynecologic Surgery, Gustave Roussy Cancer Campus, 114, rue Edouard vaillant, 94800, Villejuif, France.
  • Department of Pathology, Hautepierre Hospital, Strasbourg University Hospital, 1 avenue Molière, 67200, Strasbourg, France.
  • Department of Pathology, Gustave Roussy Cancer Campus, 114, rue Edouard vaillant, 94800, Villejuif, France.
  • Department of General and Oncological Surgery, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 Chemin du grand Revoyet, 69310, Pierre-Bénite, France.
  • Department of Surgical Oncology, François Baclesse Institute, 3 avenue du general Harris, 14000, Caen, France.
  • Department of Digestive Surgery, Clermont-Ferrand University Hospital, 1 rue Lucie et Raymond Aubrac, 63100, Clermont-Ferrand, France.
  • Department of Surgical Oncology, Montpellier Cancer Center, 208 avenue des apothicaires, 34298, Montpellier, France.
  • Department of Surgical Oncology, Claudius Regaud Insitute, 20-24 rue du pont Saint-Pierre, 31300, Toulouse, France.
  • Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University Hospital, 1 avenue Molière, 67200, Strasbourg, France.

Abstract

PURPOSE

Psammocarcinoma (PK) is a rare disease of unknown origin. We aimed to report the characteristics, management and survival of patients operated on for PK within the French Network for Rare Peritoneal Malignancies (RENAPE) expert centers.

PATIENTS AND METHODS

All consecutive cases of PK operated within all 26 RENAPE centers between 1997 and 2018 were retrospectively analyzed.

RESULTS

Twenty-five patients were identified. The median age was 53 years [range 17-78]. None of the patients had extra peritoneal metastases at diagnosis. A median of 6 cycles of carboplatin-based systemic chemotherapy was delivered in 52% preoperatively (n = 13) and 56% postoperatively (n = 14); associated with placlitaxel for 12 patients. All patients were operated on. The median PCI was 23 [0-33]. Eighty-four percent had a complete cytoreductive surgery through digestive (n = 7), spleen (n = 3), pancreas (n = 1) resections and/or multiple peritonectomies (n = 11). Five patients (20%) had intraperitoneal chemotherapy. Morbidity (Dindo-Clavien ≥3) was 12%. No postoperative death occurred. After a median follow-up of 42 months (range [2-194]), the median overall (OS) and progression-free (DFS) survival times were respectively 128 months and 31 months. Eighteen patients recurred (72%), mainly in the peritoneum (n = 16). Four of them (22%) were reoperated. The 5 and 10-year DFS rates were both 20.3%. The 5 and 10-year OS rates were 62% and 51.7%, respectively. A complete cytoreductive surgery was associated with a better OS and DFS in a univariate analysis.

CONCLUSION

Complete cytoreductive surgery is the cornerstone of the PK's management as a primary treatment. Recurrence remains common and new adjuvant strategies seem needed.

MeSH

Medical Oncology, Chemotherapy

Cited by